Literature DB >> 32904079

A long-term survival case following salvage stereotactic radiotherapy for local recurrence after definitive chemoradiotherapy for stage III non-small cell lung cancer.

Yuta Sato1, Keiichi Jingu1, Rei Umezawa1, Takaya Yamamoto1, Yojiro Ishikawa1, Kazuya Takeda1, Yu Suzuki1, Haruo Matsushita1.   

Abstract

A 56-year-old male with stage IIIA (UICC 7th) non-small cell lung cancer (adenocarcinoma) received radiotherapy with 66 Gy/33 fractions concomitant with CBDCA and PTX. A partial response was achieved after chemoradiotherapy and the tumor continued to shrink over a period of 1 year; however, regrowth of the tumor attached to the aortic arch was observed without any other residual tumor or metastases. We diagnosed recurrence with slightly increased 18F-FDG uptake (maximum standardized uptake value: 12.2). Stereotactic radiotherapy was performed for the relapsed lesion with 60 Gy/10 fractions. The patient has survived for more than 5 years after stereotactic radiotherapy without recurrence or metastases, although he has been suffering from chest pain that has required treatment with a low dose of oxycodone. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Definitive chemoradiotherapy; Non-small cell lung cancer; Salvage stereotactic radiotherapy

Year:  2020        PMID: 32904079      PMCID: PMC7450021          DOI: 10.1007/s13691-020-00431-5

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  9 in total

1.  Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

Authors:  Hiroshi Onishi; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Masaharu Fujino; Kotaro Gomi; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada; Tsutomu Araki
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

2.  Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

Authors:  James L Gulley; Arun Rajan; David R Spigel; Nicholas Iannotti; Jason Chandler; Deborah J L Wong; Joseph Leach; W Jeff Edenfield; Ding Wang; Hans Juergen Grote; Anja von Heydebreck; Kevin Chin; Jean-Marie Cuillerot; Karen Kelly
Journal:  Lancet Oncol       Date:  2017-03-31       Impact factor: 41.316

3.  A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Masashi Koto; Yoshihiro Takai; Yoshihiro Ogawa; Haruo Matsushita; Ken Takeda; Chiaki Takahashi; Keith R Britton; Kei-ichi Jingu; Kenji Takai; Masatoshi Mitsuya; Kenji Nemoto; Shogo Yamada
Journal:  Radiother Oncol       Date:  2007-11-26       Impact factor: 6.280

Review 4.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2013-02-22       Impact factor: 6.280

5.  Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.

Authors:  Shalini Garg; Benjamin T Gielda; Krystyna Kiel; Julius V Turian; Mary Jo Fidler; Marta Batus; Philip Bonomi; David J Sher
Journal:  Pract Radiat Oncol       Date:  2014-01-16

6.  Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.

Authors:  Yasushi Nagata; Masahiro Hiraoka; Taro Shibata; Hiroshi Onishi; Masaki Kokubo; Katsuyuki Karasawa; Yoshiyuki Shioyama; Rikiya Onimaru; Takuyo Kozuka; Etsuo Kunieda; Tsutomu Saito; Keiichi Nakagawa; Masato Hareyama; Yoshihiro Takai; Kazushige Hayakawa; Norio Mitsuhashi; Satoshi Ishikura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-11       Impact factor: 7.038

Review 7.  Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review.

Authors:  Arya Amini; Norman Yeh; Laurie E Gaspar; Brian Kavanagh; Sana D Karam
Journal:  Radiat Oncol       Date:  2014-09-19       Impact factor: 3.481

8.  Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.

Authors:  Yuko Shirata; Keiichi Jingu; Masashi Koto; Masaki Kubozono; Ken Takeda; Toshiyuki Sugawara; Noriyuki Kadoya; Haruo Matsushita
Journal:  Radiat Oncol       Date:  2012-10-31       Impact factor: 3.481

9.  Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.

Authors:  Marco Trovo; Emilio Minatel; Elena Durofil; Jerry Polesel; Michele Avanzo; Tania Baresic; Alessandra Bearz; Alessandro Del Conte; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Mauro G Trovo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 8.013

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.